Core Insights - The beauty and personal care sector has emerged as a key driver of sales during the "618" shopping festival, with significant year-on-year growth in sales for various beauty brands [1][2] - The medical aesthetics industry is experiencing rapid technological advancements and product innovations, leading to a diversified development landscape [1] - Domestic beauty brands are gaining competitive advantages through high cost-performance ratios and refined operations, indicating strong future growth potential in the beauty and personal care segment [1] E-commerce Performance - During the "618" promotion, beauty care products showed robust growth, with platforms like Tmall and JD.com reporting significant sales increases [1] - JD.com's data revealed that on May 20, sales of perfume and makeup sets surged nearly 300% year-on-year, with other categories like lipsticks and serums also seeing over 100% growth [1] - Tmall's data indicated that several beauty brands, including Proya and Lancôme, achieved over 100 million yuan in sales within minutes of the promotion's start [2] Product Innovation and Development - Companies are intensifying their focus on the beauty care sector, leveraging technological breakthroughs to gain competitive advantages [2][3] - Lepu Medical has expanded into ophthalmology and dermatology, recently receiving regulatory approval for a new facial filler product [3] - Proya launched a medical-grade collagen patch, while Jinbo Bio has introduced a new type of injectable collagen gel, marking significant advancements in their respective fields [3] Financial Performance and Market Trends - The beauty and personal care industry is witnessing a positive trend in net profit growth among several companies, with Jinbo Bio reporting a 62.51% increase in revenue and a 66.25% rise in net profit for Q1 2025 [4] - The demand for beauty care products is highly sensitive to new consumer trends, positioning them as a primary growth area in the market [4] - The high added value and profit margins of beauty care products, combined with the rapid innovation cycle, are driving structural growth opportunities for brands in the sector [4]

Core Insights - Yang Xia, founder of Jinbo Biotechnology, has become the richest woman in Shanxi with a wealth of 11.5 billion yuan, as reported in the 2025 Hurun Global Rich List [3][4] - Jinbo Biotechnology has made significant advancements in recombinant human collagen, leading to its successful listing on the capital market and becoming a leader in the industry [3][11] - Despite the impressive growth in revenue and net profit since its listing, Jinbo Biotechnology faces challenges such as slowing growth rates and high sales expenses [13][15] Company Overview - Jinbo Biotechnology specializes in the research, production, and sales of high-end implantable medical devices using recombinant human collagen as a core material [12] - The company's products are primarily used in medical aesthetics, surgical repair, and various medical fields [12] Financial Performance - Since its listing in 2023, Jinbo Biotechnology reported revenues of 780 million yuan and 1.443 billion yuan for 2023 and 2024, respectively, with growth rates of 99.96% and 84.92% [13] - In Q1 2025, the company achieved revenues of 366 million yuan and a net profit of 169 million yuan, with year-on-year growth rates of 62.51% and 66.25% [13] - The gross margin of Jinbo Biotechnology has been impressive, reaching 92.02% in 2024, although it saw a decline to 90.11% in Q1 2025 [15] Shareholder Dynamics - Yang Xia holds 58.89% of Jinbo Biotechnology's shares, maintaining significant control over the company [6][5] - Several shareholders have reduced their holdings, with a notable decrease in institutional ownership from 102 to 52 institutions [16][15] Market Position - Jinbo Biotechnology's current price-to-earnings ratio (TTM) stands at 53.13, higher than competitors such as Aimeike and Juzhibio [17] - The company's stock price has increased significantly, with a rise of 112.35% since January 15, 2025, reaching a market capitalization of approximately 42.477 billion yuan [8][19]

Core Viewpoint - The article highlights the significance of the New Fortune Gold Medal Secretary selection in the Chinese capital market, emphasizing the role of outstanding secretaries in enhancing corporate governance and investor relations, thus contributing to high-quality market development [1]. Company Overview - Jinbo Biological was established in 2008 and is headquartered in Taiyuan, Shanxi. It is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province. The company focuses on the research and industrialization of recombinant humanized collagen [5]. Key Achievements - Jinbo Biological became the first A-share listed company in China centered on "recombinant humanized collagen" after successfully completing its listing on July 20, 2023, on the Beijing Stock Exchange. This milestone serves as a model for the industrialization of original achievements by small and medium-sized enterprises in China [3]. - The company has received multiple approvals for innovative medical devices, including the first medical device product in China using new biological materials, and has established itself as a leader in the production of implant-grade medical devices globally [6][7]. Technological Breakthroughs - Jinbo Biological has achieved three core technological breakthroughs: 1. Safety breakthrough with a protein amino acid sequence highly consistent with natural collagen, showing strong biocompatibility and no immunogenic issues in over 2 million clinical applications [8]. 2. Effectiveness breakthrough with a clear 164.88° flexible triple helix structure, recognized by the international protein database [8]. 3. Application scenario breakthrough with high cell adhesion surpassing natural collagen, demonstrating excellent tissue repair characteristics across various fields [8]. Innovation Strategy - The company adheres to an "original innovation" strategy, having established six major technology platforms and multiple joint research platforms with prestigious institutions, covering the entire chain from basic research to clinical transformation and industrial implementation [9]. Role of the Secretary - The role of the board secretary is crucial in bridging the company and the capital market, requiring solid financial and legal knowledge, as well as excellent communication and coordination skills. The secretary's responsibilities include ensuring compliance, enhancing communication with regulatory bodies, investors, and media, and fostering a transparent public relations environment [14].

Group 1: Company Position and Technology Advantages - The company is a leader in the field of recombinant human collagen, being the only enterprise capable of industrial-scale production of recombinant type III human collagen [5] - It has achieved significant breakthroughs in safety, efficacy, and application scenarios, with over 2 million clinical applications and no observed immunogenicity [5] - The recombinant type III human collagen has a specific 164.88° flexible triple helix structure, with high biological activity recognized by the international protein structure database (PDB) [5] Group 2: Product Launch and Market Strategy - The new product "Wei Yi Mei ColNet," launched in February 2025, is positioned as a high-end product with a specification of 12mg per unit, currently distributed to approximately 100 outlets [6] - The company plans to expand its product system under the "Wei Yi Mei" brand to meet diverse consumer needs and will continue to increase its coverage of medical institutions, which currently includes about 4,000 institutions [9] Group 3: Future Research and Development Focus - The company will deepen the application development of recombinant type III human collagen across various medical fields, including dermatology, gynecology, urology, orthopedics, and cardiovascular [7] - It is also exploring other types of collagen, such as recombinant type XVII and type V human collagen, with some products already in clinical trial stages [7] Group 4: Functional Skincare Products - The sales revenue of functional skincare products is expected to grow rapidly in 2024, driven by the performance of proprietary brands like "Zhongyuan®" and "ProtYouth®" [10] - The sales strategy for 2025 includes building proprietary brands around innovative material advantages and developing raw materials tailored to major customer needs [10]

证券简称： 锦波生物 证券代码： 832982 山西锦波生物医药股份有限公司 山西综改示范区太原唐槐园区锦波街 18 号 山西锦波生物医药股份有限公司招股说明书 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 1-1-0 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自行负 责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发行后因发 行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 声明 发行人 ...

证券简称： 锦波生物 证券代码： 832982 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 山西锦波生物医药股份有限公司招股说明书（申报稿） 山西综改示范区太原唐槐园区锦波街 18 号 山西锦波生物医药股份有限公司 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 1-1-0 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 慎作出投资决定。 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自行负 责 ...

证券简称： 锦波生物 证券代码： 832982 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 山西锦波生物医药股份有限公司招股说明书（申报稿） 山西综改示范区太原唐槐园区锦波街 18 号 山西锦波生物医药股份有限公司 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 1-1-0 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 慎作出投资决定。 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自行负 责 ...

证券简称： 锦波生物 证券代码： 832982 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 山西综改示范区太原唐槐园区锦波街 18 号 山西锦波生物医药股份有限公司招股说明书（申报稿） 山西锦波生物医药股份有限公司 慎作出投资决定。 1-1-0 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自行负 责 ...